Risk of relapse (as defined by study authors) (HR) · participants with long‐term antidepressants for depressive disorders
Discontinuation with high‐intensity psychological interventions showed no clear difference in risk of relapse (as defined by study authors) (HR) compared with continuation (low certainty).
1 finding from 1 review
Withdrawal symptoms · participants with long‐term antidepressants for depressive disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · participants with long‐term antidepressants for depressive disorders
1 finding from 1 review
Depressive symptoms · participants with long‐term antidepressants for depressive disorders
1 finding from 1 review
Anxiety · participants with long‐term antidepressants for depressive disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · participants with long‐term antidepressants for depressive disorders
1 finding from 1 review
Social and occupational functioning · participants with long‐term antidepressants for depressive disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (OS) · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate (ORR), · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (high dose interferon) plus chemotherapy changes overall response rate (ORR), measured after 8 weeks of treatment and… compared with neoadjuvant chemotherapy (very low certainty).
1 finding from 1 review
Time to recurrence ‐ not measured · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).
1 finding from 1 review
Clinical improvement: discharged alive ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in clinical improvement: discharged alive ( compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Adverse events: all grades · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Hospital‐acquired infections ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Invasive fungal infection · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review